Boston Scientific Corporation (NYSE:BSX) Short Interest Update

Boston Scientific Corporation (NYSE:BSX) saw a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 29,750,309 shares, a decrease of 48.3% from the May 31st total of 57,491,117 shares. Based on an average daily volume of 20,617,498 shares, the short-interest ratio is presently 1.4 days. Currently, 2.0% of the company’s stock are short sold.

Insider Activity

In other Boston Scientific news, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter worth about $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific during the 4th quarter worth about $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific during the 4th quarter worth about $26,000. Bangor Savings Bank raised its stake in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund purchased a new position in Boston Scientific in the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock traded up $2.03 during midday trading on Thursday, reaching $45.09. The company’s stock had a trading volume of 26,336,601 shares, compared to its average volume of 18,290,291. The firm has a market capitalization of $67.01 billion, a PE ratio of 18.86, a P/E/G ratio of 0.82 and a beta of 0.56. Boston Scientific has a fifty-two week low of $42.25 and a fifty-two week high of $109.50. The stock’s 50 day simple moving average is $51.68 and its 200 day simple moving average is $69.93. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts forecast that Boston Scientific will post 3.36 earnings per share for the current year.

Boston Scientific announced that its board has approved a share buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Piper Sandler reissued an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a report on Friday, June 12th. Zacks Research lowered Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Mizuho cut their price target on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Oppenheimer set a $90.00 price target on Boston Scientific in a report on Thursday, April 23rd. Finally, Robert W. Baird set a $70.00 target price on shares of Boston Scientific in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $83.36.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.